Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Entity

Novartis — Sandoz

Tracked across 8 events · 68 articles · First seen Oct 29, 2025 · Last active Sep 18, 2026

Sentiment
8
Attention
6
Events
8
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
1 20
Business
Impact: Novartis — Sandoz Malaysia co-launched the initiative, supplying affordable medicines and strengthening its position in the Malaysian cardiovascular market, potentially increasing sales of stroke prevention drugs.
Sep 03, 2026 · 6 articles
2 20
Business
mAbxience, a majority-owned company of Fresenius (company) with partial ownership from Insud Pharma, and Novartis — Sandoz announced a licensing, development, manufacturing and commercialization agreement for a proposed emicizumab biosimilar candidate referencing Hemlibra, indicated for…
Impact: Novartis — Sandoz secures exclusive global commercialization rights outside Argentina, Uruguay, and Paraguay, strengthening its biosimilars portfolio and long-term growth outlook.
Sep 18, 2026 · 8 articles
4 10
Tech
Impact: Novartis — Sandoz validated the J.TRAIN model through a December 2025 transaction, which included a manufacturing facility and a license to Evotec's proprietary manufacturing technology, demonstrating the feasibility and scalability of the new offering.
Jun 30, 2026 · 7 articles
2 0
Business
Impact: Nimish Muzumdar previously served as Senior Vice President & Head, Generics at Novartis — Sandoz before joining Embecta.
Jun 16, 2026 · 6 articles
6 0
Business
Novartis announced on September 8, 2026 that its Phase III HARBOR study of del-desiran, an antibody oligonucleotide conjugate for myotonic dystrophy type 1 (DM1), failed to show statistically significant improvement versus placebo on the primary…
Impact: Novartis — Sandoz, spun off from Novartis in 2023, has reportedly outperformed Novartis, adding to analyst criticism of the parent company's strategic direction.
Sep 08, 2026 · 21 articles
4 0
Business
Impact: Novartis — Sandoz expanded its development and commercialization partnership with Samsung Biologics — Samsung Biologics for biosimilar candidates.
Apr 23, 2026 · 6 articles
2 10
Domestic
Impact: Novartis — Sandoz>>> ended on a firm note and gained 1%-1.5%, contributing to the positive close of the Switzerland>>> market.
May 21, 2026 · 8 articles
1 0
Business
Impact: Patrick Vink held senior executive roles at Novartis — Sandoz.
Jul 08, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Novartis — Sandoz live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.